Pamela T. A.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
- Phase 3 Randomized Open‑Label Study of ZL‑1310 versus Investigator‑Chosen Topotecan in Relapsed Small Cell Lung Cancer
- Phase III Randomized Study of Volrustomig with Carboplatin and Pemetrexed Versus Standard Care in Unresectable Pleural Mesothelioma
- Phase 3 Multicenter Randomized Open-label Study of Ifinatamab Deruxtecan Versus Physician's Choice in Relapsed Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 87 of 245 partner sites.
Specializations
Oncology Focus
The investigator specializes in treating small cell lung cancer (SCLC), with particular emphasis on developing innovative therapeutic approaches for patients with relapsed disease.
- Advanced lung cancer therapeutics
- Relapsed SCLC management
- Treatment response assessment
The investigator evaluates novel therapeutic strategies in thoracic oncology, focusing on improving survival outcomes for patients with aggressive forms of lung cancer.
Clinical Assessment
Expertise in measuring treatment efficacy through objective response rate (ORR) and overall survival (OS) metrics in thoracic malignancies.
- Response evaluation criteria
- Survival outcome analysis
- Comparative treatment assessment
The investigator employs comprehensive evaluation methods to assess therapeutic effectiveness in advanced lung cancer treatments.
Treatment Innovation
Focuses on comparing emerging therapies with standard of care (SoC) approaches in thoracic oncology.
- Novel therapeutic development
- Treatment comparison studies
- Advanced care protocols
The investigator explores new therapeutic options aimed at improving outcomes for patients with resistant or recurrent lung cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.